OncoTherapy Science, Inc. is a Japan-based company mainly engaged in the development of drugs. The Company is involved in the development of low molecular drugs, antibody drugs and other drugs, as well as the provision and clinical development of medical candidate substances. The Company operates its business in cooperation with universities and other corporations. The Company provides its licenses to pharmaceutical manufacturers. The Company also involves in T Cell Receptor(TCR) analysis business.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-08-20	JP¥21.00	+5.00%	201,642,500
26-08-19	JP¥20.00	-4.76%	226,637,600
26-08-18	JP¥21.00	-4.55%	175,735,800
26-08-17	JP¥22.00	+10.00%	224,056,100
26-08-14	JP¥20.00	0.00%	206,541,400

Delayed Quote Japan Exchange

More quotes

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Japan Exchange 02:30:00 2026-08-20 EDT			5-day change	1st Jan Change
21.00 ^JPY	+5.00%		+5.00%	+5.00%

25-06-23	OncoTherapy Science, Inc. Auditor Raises 'Going Concern' Doubt	CI
25-04-27	OncoTherapy Science, Inc. announced that it has received ¥84.87 million in funding from Long Corridor Asset Management Limited	CI

Market Cap	8.57B 53.9M 46.15M 43.13M 39.55M 74.29M 5.16B 75.79M 507M 199M 2.59B 202M 198M	P/E 2025	-8.97x	P/E 2026	-7.57x
Enterprise Value	6.48B 40.77M 34.9M 32.62M 29.91M 56.18M 3.9B 57.33M 383M 150M 1.96B 153M 150M	EV / Sales 2025	9.03x	EV / Sales 2026	7.39x
Free-Float	88.54%	Yield 2025 *	-	Yield 2026	-

25-06-23	OncoTherapy Science, Inc. Auditor Raises 'Going Concern' Doubt	CI
25-04-27	OncoTherapy Science, Inc. announced that it has received ¥84.87 million in funding from Long Corridor Asset Management Limited	CI
25-04-09	OncoTherapy Science, Inc. announced that it expects to receive ¥84.87 million in funding	CI
24-04-29	Poland's Tusk calls prosecutor over potential Orlen scandal	RE
24-04-21	OncoTherapy Science, Inc. cancelled the transaction announced on April 5, 2024	CI
24-04-04	OncoTherapy Science, Inc. announced that it expects to receive ¥3.78 million in funding from Long Corridor Asset Management Limited and another investor	CI
23-09-18	OncoTherapy Science, Inc.(TSE:4564) dropped from S&P Global BMI Index	CI
23-05-12	OncoTherapy Science, Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	CI
23-04-09	OncoTherapy Science, Inc. announced that it has received ¥95.95 million in funding	CI
23-03-23	OncoTherapy Science, Inc. announced that it expects to receive ¥95.95 million in funding	CI
21-04-27	OncoTherapy Science, Inc. announced that it has received ¥12.25 million in funding from Daiwa Securities Co., Ltd., Investment Arm	CI
21-04-11	OncoTherapy Science, Inc. announced that it expects to receive ¥12.25 million in funding from Daiwa Securities Co., Ltd., Investment Arm	CI
19-01-14	OncoTherapy Science, Inc. announced that it has received ¥12.013 million in funding from Daiwa Securities Group Inc.	CI

24-05-14	Triple Negative Breast Cancer Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)	AQ
23-12-05	Triple Negative Breast Cancer Pipeline, FDA Approvals, Clinical Trials Assessment, Companies 2023 \| Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 Therapeutics, Inc., and others.	AQ
22-09-12	OncoTherapy Science : Announcement of the Presentation of Interim Results for Phase I Clinical Study of a Combination of OTSGC-A24 and Immune Checkpoint Inhibitor in Patients with Gastric Cancer	PU
20-10-01	OncoTherapy Science : Japanese bio-venture starts development of COVID-19 peptide vaccine	AQ

OncoTherapy Science, Inc. Stock

Stocks

4564

JP3202150003

Biotechnology & Medical Research

Valuation: OncoTherapy Science, Inc.

Chart: OncoTherapy Science, Inc.

Latest news : OncoTherapy Science, Inc.

Press Releases: OncoTherapy Science, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: OncoTherapy Science, Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Quarterly revenue - Rate of surprise

1 day	+5.00%
1 week	+5.00%
Current month	+10.53%
1 month	+5.00%
3 months	+5.00%
Current year	+5.00%

Manager	Title	Age	Since
Junichi Shimada PSD	President	65	2022-06-30
Zehyon Paku PSD	President	50	2019-12-04
Yuka Yamane CTO	Chief Tech/Sci/R&D Officer	53	2012-07-31

Director	Title	Age	Since
Yuichi Komine BRD	Director/Board Member	54	2014-08-31
Zehyon Paku BRD	Director/Board Member	50	2018-05-31
Hatsuo Kato CHM	Chairman	82	2020-05-31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ONCOTHERAPY SCIENCE, INC.	+5.00%	+5.00%	-22.22%	-25.00%	51.51M
WUXI APPTEC CO., LTD.	+2.38%	+5.57%	+86.02%	+115.89%	72.21B
ARGENX SE	+0.87%	+16.32%	+58.35%	+97.28%	63.98B
INSMED INCORPORATED	-4.27%	-5.44%	-1.67%	+475.61%	28.53B
WUXI BIOLOGICS (CAYMAN) INC.	+3.63%	+8.62%	+66.69%	+23.95%	25.07B
BIONTECH SE	-1.97%	+19.57%	-0.46%	+0.48%	28.42B
GENMAB A/S	-0.51%	+5.11%	+41.27%	-12.79%	20.04B
PHARMAESSENTIA CORPORATION	-1.79%	-4.51%	+241.26%	+414.48%	18.19B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+1.81%	+0.85%	+16.89%	+546.06%	15.96B
EXELIXIS, INC.	-1.29%	+6.57%	+43.10%	+154.45%	13.48B
Average	+0.39%	+5.07%	+52.92%	+179.04%	28.59B
Weighted average by Cap.	+0.38%	+7.47%	+61.63%	+163.88%

	2025	2026
Net sales	750M 4.72M 4.04M 3.77M 3.46M 6.5M 451M 6.63M 44.34M 17.38M 227M 17.7M 17.32M	808M 5.08M 4.35M 4.07M 3.73M 7M 486M 7.14M 47.77M 18.72M 244M 19.07M 18.66M
Net income	-815M -5.12M -4.39M -4.1M -3.76M -7.06M -490M -7.21M -48.18M -18.88M -246M -19.24M -18.82M	-910M -5.72M -4.9M -4.58M -4.2M -7.89M -547M -8.05M -53.8M -21.08M -275M -21.48M -21.02M
Net Debt	-833M -5.24M -4.48M -4.19M -3.84M -7.22M -501M -7.36M -49.25M -19.3M -252M -19.66M -19.24M	-2.09B -13.13M -11.25M -10.51M -9.64M -18.1M -1.26B -18.47M -124M -48.4M -632M -49.31M -48.24M